Angiolutions specializes in device-based innovation in vascular medicine. Through its latest award-winning technology, the company aims to prevent the deadly progression of small abdominal aortic aneurysms.
An abdominal aortic aneurysm is a bulging of the abdominal aorta. With a growing aneurysm diameter, the risk of fatal rupture increases. While this progressive disease affects a substantial number of patients worldwide, there is no therapy available to stop aneurysm growth. Based on latest research findings, that the founding team acquired during its academic work, Angiolutions aims to stop aneurysm progression at an early stage.

Press releases

12. January 2023

Start-up stories: From science to business

Their first pitch deck didn’t contain a business slide. And there wasn’t any information on market potential. These were things that Dr Isabel Schellinger and Dr Uwe Raaz simply hadn’t thought of. After all, their focus was on their research, on the amazing opportunities made possible thanks to science, and on a medical solution to an aortic disorder in humans that they had developed. This is their passion and their field of expertise. Pitching to investors and founding a start-up were
Gründerteam Angiolutions
17. February 2021

Angiolutions’ novel vascular implant defuses the abdominal ticking time bomb

The award-winning team of the medtech startup Angiolutions successfully secured its seed financing round with High-Tech Gründerfonds, FRIBA Investment and NBank Capital. Based on the founders’ research, the company aims to prevent the deadly progression of small abdominal aortic aneurysms. We are thrilled to work with a strong investor syndicate enabling the successful completion of our critical R&D steps.Dr. Uwe Raaz and Dr. Isabel N. Schellinger, founders of Angiolutions

Info & Contact


Ludwig-Thoma-Strasse 15e
91054 Erlangen

In portfolio

09. Dec 2020


HTGF Manager

Dr. Anke Caßing, Principal / Authorized Signatory